Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immunome, Inc. (IMNM : NSDQ)
 
 • Company Description   
Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

Number of Employees: 39

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.35 Daily Weekly Monthly
20 Day Moving Average: 109,556 shares
Shares Outstanding: 12.13 (millions)
Market Capitalization: $40.63 (millions)
Beta: 0.03
52 Week High: $27.80
52 Week Low: $2.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.99% -11.01%
12 Week -52.14% -47.38%
Year To Date -74.15% -68.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
665 STOCKTON DRIVE SUITE 300
-
EXTON,PA 19341
USA
ph: 610-321-3700
fax: -
investors@immunome.com https://immunome.com
 
 • General Corporate Information   
Officers
Purnanand D. Sarma - President; Chief Executive Officer and Director
Corleen M. Roche - Chief Financial Officer
Michael Rapp - Director
Richard Baron - Director
John LaMattina - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45257U108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 12.13
Most Recent Split Date: (:1)
Beta: 0.03
Market Capitalization: $40.63 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.96 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.07
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -159.46%
vs. Previous Quarter: -45.45%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -64.46
12/31/21 - -49.06
09/30/21 - -43.02
ROA
03/31/22 - -55.89
12/31/21 - -43.50
09/30/21 - -39.16
Current Ratio
03/31/22 - 4.77
12/31/21 - 5.82
09/30/21 - 7.88
Quick Ratio
03/31/22 - 4.77
12/31/21 - 5.82
09/30/21 - 7.88
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.12
12/31/21 - 3.98
09/30/21 - 4.53
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©